Abstract
The analysis of the results of a study investigating the effectiveness of various modifications of prevailing drug treatment regimens of malignant lymphomas (non-Hodgkin's lymphoma and Hodgkin's lymphoma) is presented. The choice of optimal treatment is a complex problem, especially in patients with a high degree of tumor cells chemoresistance. The authors discuss the treatment options of different types of lymphomas using not only standard regimens, but also those that include drugs, depending on the age characteristics and individual tolerance, which allows in some cases significantly reduce the time of a relapse-free course and lower incidence of side effects of cytostatics on different organs and tissues. Intensified therapy for all aggressive non-Hodgkin's lymphomas with a high proliferative index allows 90% of the time to obtain a complete clinical and hematological remission. In Hodgkin's lymphomas the use of such programs helps to increase the duration of recurrence-free interval by persistent complete remission. The proposed regimen is highly effective in the treatment of patients with concomitant viral hepatitis and HIV infection. Drug therapy with the use of the proposed programs is a safe method of drug exposure, its side effects are minimal, and it is well tolerated by patients.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
